Severe FECD increases risk of glaucoma and OHT

Article

Severe Fuchs endothelial corneal dystrophy (FECD) increases the risk of developing glaucoma and/or ocular hypertension (G/OHT).

Severe Fuchs endothelial corneal dystrophy (FECD) increases the risk of developing glaucoma and/or ocular hypertension (G/OHT).

Dr Mehul Nagarsheth et al., Wills Eye Institute/Jefferson Medical College, Philadelphia, Pennsylvania, USA, studied a subset of 1610 from the FECD Genetics Multi-Centre Study. Logistic regression models, adjusted for age, sex, central corneal thickness, IOP, presence of diabetes and time of day of the initial evaluation, were used.

Of the total eyes included in the study, 107 eyes had G/OHT and the prevalence of G/OHT in the control group was 6%. Eyes with a grade of four through to six were more likely to have concurrent G/OHT than eyes with no record of FECD.

Prevalence of G/OHT was lower in index cases with an FECD grade of one to three and family members with a grade of zero through to three. But it was higher in index cases and family members with a grade of four to six. The logistic regression models demonstrated no correlation between sex, diabetes, time of day of evaluation and central corneal thickness with prevalence of G/OHT.

The abstract can be found in the journal Archives of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.